Rationale: Whether pharmacological therapy alters decline in FEV1 in chronic obstructive
pulmonary disease remains controversial. Because pharmacotherapy improves health …

Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by an
accelerated decline in lung function. No drug has been shown conclusively to reduce this …

Background In clinical trials of inhaled bronchodilators, chronic obstructive pulmonary
disease (COPD) guidelines recommend that patient-reported outcomes (PROs) are …

Rationale: Many patients with chronic obstructive pulmonary disease (COPD) have an
accelerated loss of lung function. It is unclear whether drug treatment can modify this in …

Background Relationships between improvements in lung function and other clinical
outcomes in chronic obstructive pulmonary disease (COPD) are not documented …

The wide distribution of individual rates of decline in FEV 1 includes especially rapid and
slow declines. Future research is needed to identify biomarkers that both are predictive of a …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation that is not fully reversible (1). Like many other major chronic diseases the burden …

Rationale: Although the rate of annual decline in FEV1 is one of the most important outcome
measures in chronic obstructive pulmonary disease (COPD), little is known about …

Background: Most patients with moderate and severe chronic obstructive pulmonary disease
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …

Clinical phenotyping is currently used to guide pharmacological treatment decisions in
chronic obstructive pulmonary disease (COPD), a personalized approach to care. Precision …